US4797410A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Suppression of withdrawal symptoms in opioid-induced tolerance or dependence
Assignee: Bayer Corp
•
Filing: 1987-04-16
•
Granted: 1989-01-10
•
Expires: 2007-04-16
Abstract
Abstract A method for suppressing withdrawal symptoms in an opioid-induced tolerant or physically dependent individual is disclosed. The method comprises administering to such individual an effective amount of a calcium channel blocking drug or pharmaceutically acceptable non-toxic salt thereof to suppress said withdrawal in said individual. Also disclosed are pharmaceutical compositions suitable for use in suppressing withdrawal symptoms in an opioid-induced tolerant or physically dependent individual.
Inventors
- 👤 Esam E. El-Fakahany
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 20:04
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/275; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61P; A61P25/00; A61P25/30; A61P3/00; A61P3/12; A61P3/14; A61P9/00; A61P9/08
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
84 words
A method for suppressing withdrawal symptoms in an opioid-induced tolerant or physically dependent individual, said withdrawal symptoms selected from the group consisting of: (a) the sympathetic effects of lacrimation, rhinorrhea, sweating, piloerection, dilated pupils and elevated pulse rate; (b) parasympathetic effects; (c) behavioral hyperexcitability; (d) muscle and joint pain; and (e) ptosis, said method comprising administering to said individual an effective amount of a 1,4-dihydropyridine calcium channel blocking drug or a pharmaceutically acceptable non-toxic salt thereof to suppress said withdrawal symptoms in said individual.
Claim 2
Independent Claim
84 words
A method for suppressing withdrawal symptoms in an opioid-induced tolerant or physically dependent individual, said withdrawal symptoms selected from the group consisting of: (a) the sympathetic effects of lacrimation, rhinorrhea, sweating, piloerection, dilated pupils and elevated pulse rate; (b) parasympathetic effects; (c) behavioral hyperexcitability; (d) muscle and joint pain; and (e) ptosis, said method comprising administering to said individual an effective amount of a 1,4-dihydropyridine calcium channel blocking drug or a pharmaceutically acceptable non-toxic salt thereof to suppress said withdrawal symptoms in said individual.
Claim 3
Independent Claim
84 words
A method for suppressing withdrawal symptoms in an opioid-induced tolerant or physically dependent individual, said withdrawal symptoms selected from the group consisting of: (a) the sympathetic effects of lacrimation, rhinorrhea, sweating, piloerection, dilated pupils and elevated pulse rate; (b) parasympathetic effects; (c) behavioral hyperexcitability; (d) muscle and joint pain; and (e) ptosis, said method comprising administering to said individual an effective amount of a β-phenethyl-amine calcium channel blocking drug or a pharmaceutically acceptable non-toxic salt thereof to suppress said withdrawal symptoms in said individual.
Claim 4
Independent Claim
84 words
A method for suppressing withdrawal symptoms in an opioid-induced tolerant or physically dependent individual, said withdrawal symptoms selected from the group consisting of: (a) the sympathetic effects of lacrimation, rhinorrhea, sweating, piloerection, dilated pupils and elevated pulse rate; (b) parasympathetic effects; (c) behavioral hyperexcitability; (d) muscle and joint pain; and (e) ptosis, said method comprising administering to said individual an effective amount of a β-phenethyl-amine calcium channel blocking drug or a pharmaceutically acceptable non-toxic salt thereof to suppress said withdrawal symptoms in said individual.
Claim 5
Dependent Claim
14 words
The method of claim 1 wherein the 1,4-dihydropyridine calcium channel blocking drug is nisoldipine.
Claim 6
Dependent Claim
14 words
The method of claim 1 wherein the 1,4-dihydropyridine calcium channel blocking drug is nifedipine.
Claim 7
Dependent Claim
14 words
The method of claim 1 wherein the 1,4-dihydropyridine calcium channel blocking drug is nimodipine.
Claim 8
Dependent Claim
14 words
The method of claim 2 wherein the β-phenethylamine calcium channel blocking drug is verapamil.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-01-10 | 1992-07-11 | 1993-01-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-01-10 | 1996-07-11 | 1997-01-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-01-10 | 2000-07-11 | 2001-01-10 | $7700.00 | Window Closed / Lapsed |